347 related articles for article (PubMed ID: 31952675)
1. Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention.
Dong OM; Wheeler SB; Cruden G; Lee CR; Voora D; Dusetzina SB; Wiltshire T
Value Health; 2020 Jan; 23(1):61-73. PubMed ID: 31952675
[TBL] [Abstract][Full Text] [Related]
2. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
Jiang M; You JH
Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Strategies to Personalize the Selection of P2Y
Kim K; Touchette DR; Cavallari LH; Ardati AK; DiDomenico RJ
Cardiovasc Drugs Ther; 2019 Oct; 33(5):533-546. PubMed ID: 31367811
[TBL] [Abstract][Full Text] [Related]
4. An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention.
Okere AN; Ezendu K; Berthe A; Diaby V
J Manag Care Spec Pharm; 2018 Feb; 24(2):142-152. PubMed ID: 29384027
[TBL] [Abstract][Full Text] [Related]
5. Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.
Lala A; Berger JS; Sharma G; Hochman JS; Scott Braithwaite R; Ladapo JA
J Thromb Haemost; 2013 Jan; 11(1):81-91. PubMed ID: 23137413
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden.
Verhoef TI; Redekop WK; Langenskiold S; Kamali F; Wadelius M; Burnside G; Maitland-van der Zee AH; Hughes DA; Pirmohamed M
Pharmacogenomics J; 2016 Oct; 16(5):478-84. PubMed ID: 27272045
[TBL] [Abstract][Full Text] [Related]
7. Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review.
AlMukdad S; Elewa H; Al-Badriyeh D
J Cardiovasc Pharmacol Ther; 2020 May; 25(3):201-211. PubMed ID: 32027168
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.
Jiang M; You JHS
Clin Cardiol; 2017 Oct; 40(10):789-796. PubMed ID: 28683175
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
Limdi NA; Cavallari LH; Lee CR; Hillegass WB; Holmes AM; Skaar TC; Pisu M; Dillon C; Beitelshees AL; Empey PE; Duarte JD; Diaby V; Gong Y; Johnson JA; Graves J; Garbett S; Zhou Z; Peterson JF;
Pharmacogenomics J; 2020 Oct; 20(5):724-735. PubMed ID: 32042096
[TBL] [Abstract][Full Text] [Related]
10. Clopidogrel Versus Aspirin for the Treatment of Acute Coronary Syndrome After a 12-Month Dual Antiplatelet Therapy: A Cost-effectiveness Analysis From China Payer's Perspective.
Zhang L; Lin Z; Yin H; Liu J; Xuan J
Clin Ther; 2018 Dec; 40(12):2125-2137. PubMed ID: 30470579
[TBL] [Abstract][Full Text] [Related]
11. Prasugrel compared to clopidogrel in patients with acute coronary syndrome undergoing percutenaous coronary intervention: a Spanish model-based cost effectiveness analysis.
Davies A; Sculpher M; Barrett A; Huete T; Sacristán JA; Dilla T
Farm Hosp; 2013; 37(4):307-16. PubMed ID: 24010692
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA
Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome.
Jiang M; You JH
Pharmacogenomics; 2016 May; 17(7):701-13. PubMed ID: 27167099
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of CYP2C19-guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes.
Dong OM; Friede KA; Chanfreau-Coffinier C; Voora D
Eur Heart J Qual Care Clin Outcomes; 2023 Apr; 9(3):249-257. PubMed ID: 35652783
[TBL] [Abstract][Full Text] [Related]
15. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Cavallari LH; Lee CR; Beitelshees AL; Cooper-DeHoff RM; Duarte JD; Voora D; Kimmel SE; McDonough CW; Gong Y; Dave CV; Pratt VM; Alestock TD; Anderson RD; Alsip J; Ardati AK; Brott BC; Brown L; Chumnumwat S; Clare-Salzler MJ; Coons JC; Denny JC; Dillon C; Elsey AR; Hamadeh IS; Harada S; Hillegass WB; Hines L; Horenstein RB; Howell LA; Jeng LJB; Kelemen MD; Lee YM; Magvanjav O; Montasser M; Nelson DR; Nutescu EA; Nwaba DC; Pakyz RE; Palmer K; Peterson JF; Pollin TI; Quinn AH; Robinson SW; Schub J; Skaar TC; Smith DM; Sriramoju VB; Starostik P; Stys TP; Stevenson JM; Varunok N; Vesely MR; Wake DT; Weck KE; Weitzel KW; Wilke RA; Willig J; Zhao RY; Kreutz RP; Stouffer GA; Empey PE; Limdi NA; Shuldiner AR; Winterstein AG; Johnson JA;
JACC Cardiovasc Interv; 2018 Jan; 11(2):181-191. PubMed ID: 29102571
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack.
Cai Z; Cai D; Wang R; Wang H; Yu Z; Gao F; Liu Y; Kang Y; Wu Z
Sci Rep; 2021 Apr; 11(1):7383. PubMed ID: 33795788
[TBL] [Abstract][Full Text] [Related]
17. CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.
Jiang M; You JH
Pharmacogenet Genomics; 2015 Dec; 25(12):609-17. PubMed ID: 26398625
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of
Fu Y; Zhang XY; Qin SB; Nie XY; Shi LW; Shao H; Liu J
Pharmacogenomics; 2020 Jan; 21(1):33-42. PubMed ID: 31849282
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness of cytochrome P450 2C19 *2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome.
Wang Y; Yan BP; Liew D; Lee VWY
Pharmacogenomics J; 2018 Jan; 18(1):113-120. PubMed ID: 28117433
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic guided versus standard warfarin dosing for routine clinical care with its pharmacoeconomic impact: a randomized controlled clinical trial.
Anand A; Hegde NC; Chhabra P; Purohit J; Kumar R; Gupta A; Lad DP; Mohindra R; Mehrotra S; Vijayvergiya R; Kumar B; Sharma V; Malhotra P; Ahluwalia J; Das R; Patil AN; Shafiq N; Malhotra S
Ann Hematol; 2024 Jun; 103(6):2133-2144. PubMed ID: 38634917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]